Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Sarcoma 1Gynecologic 1

Conditions

Sarcoma 32Ovarian Neoplasms 12Leiomyosarcoma 12Liposarcoma 10Neoplasms 7Sarcoma, Ewing 4Neoplasm Metastasis 4Liposarcoma, Myxoid 4Sarcoma, Synovial 3Rhabdomyosarcoma 3Histiocytoma, Malignant Fibrous 3Breast Neoplasms 3Solitary Fibrous Tumors 2Sarcoma, Alveolar Soft Part 2Prostatic Neoplasms 2Osteosarcoma 2Neurofibrosarcoma 2Neoplasms by Site 2Mesothelioma, Malignant 2Malignant mesenchymal tumor 2Ichthyosis, X-Linked 2Hemangiosarcoma 2Hemangiopericytoma, Malignant 2Fibrosarcoma 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Bone Neoplasms 2Wilms Tumor 1Uterine Neoplasms 1Unspecified Childhood Solid Tumor, Protocol Specific 1

Interventions

Trastuzumab 594Paclitaxel 561Cyclophosphamide 545Docetaxel 478Capecitabine 387Letrozole 350Fulvestrant 310Doxorubicin 285Carboplatin 277Tamoxifen 257Anastrozole 219exemestane 211Epirubicin 210Radiotherapy 197Bevacizumab 189pertuzumab 175Gemcitabine 163Vinorelbine 162pembrolizumab 161Lapatinib 161palbociclib 152Exercise 132Fluorouracil 118Albumin-Bound Paclitaxel 116eribulin 108Magnetic Resonance Spectroscopy 108130-nm albumin-bound paclitaxel 107Everolimus 103Taxes 96Cisplatin 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Breast Neoplasms × Trabectedin × Clear all
NCT00786838 2014-04-11

A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2 Completed
76 enrolled 17 charts
BreastGynecologicSarcoma

Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Sarcoma

NCT00580112 2014-02-25

An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2 Completed
127 enrolled
Breast

Breast Neoplasms

NCT00050427 2011-04-28

A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2 Completed
53 enrolled
Breast

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Skin Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡